Meeting the Challenges in Atrial Fibrillation Management: The Role of New Anticoagulants

Chairpeople:

Freek Verheugt,¹ Christoph Bode²

Speakers:

Gregory Lip,³ Raffaele De Caterina,⁴ Robert Giugliano⁵

1. Heart Lung Centre, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
2. Heart Center Freiburg University, Freiburg, Germany
3. University of Birmingham, Birmingham, UK
4. “G. d’Annunzio” University, Chieti, Italy
5. Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA

Disclosure:

Prof Gregory Lip has acted as a consultant for Bayer, Astellas, Merck, Sanofi, BMS/Pfizer, Biotronik, Medtronic, Portola, Boehringer Ingelheim, Microlife Medtronic, and Daiichi Sankyo. He has also been on the speakers’ bureau for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, and Daiichi Sankyo. Prof Raffaele De Caterina has received fees, honoraria, and research funding from Sanofi-Aventis, Boehringer Ingelheim, Bayer, BMS/Pfizer, Daiichi Sankyo, and Novartis. Prof Robert Giugliano has received research grant support from Daiichi Sankyo and Merck, and honoraria for lectures/consulting from Daiichi Sankyo, Merck, Janssen, Pfizer, and Sanofi.

Acknowledgements:

Writing assistance provided by Dr Saroshi Amirthalingam, apothecom scopemedical Ltd.

Support:

The publication of this article was funded by Daiichi Sankyo Europe GmbH. The views and opinions expressed are those of the authors and not necessarily of Daiichi Sankyo.

Citation:

EMJ Cardiol. 2014;2:38-45. DOI/10.33590/emjcardiol/10311237. https://doi.org/10.33590/emjcardiol/10311237.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.